stockportfolio.pro
Stocks / BIO vs IBRX
BIO vs IBRX
Bio-Rad Laboratories, Inc. and ImmunityBio, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bio-Rad Laboratories, Inc. (BIO) | ImmunityBio, Inc. (IBRX) | |
|---|---|---|
| Market cap | $7.8B | $7.5B |
| Revenue (latest FY) | $2.58B | $113.29M |
| Net income (latest FY) | $759.90M | $-351.40M |
| Revenue growth (5y CAGR) | 0.3% | 184.8% |
| Net margin | 29.4% | -310.2% |
| Return on equity | 10.2% | 70.2% |
| P/E ratio | 48.8 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIO — free Open IBRX — freeFrequently asked questions
Which is bigger, BIO or IBRX?
Bio-Rad Laboratories, Inc. is larger by market capitalization — $7.8B versus $7.5B.
Which grows faster, BIO or IBRX?
Over the last five fiscal years, ImmunityBio, Inc. grew revenue faster — 184.8%/yr versus 0.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.